Titre : Benzocycloheptènes

Benzocycloheptènes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Activins
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Benzocycloheptènes : Questions médicales les plus fréquentes", "headline": "Benzocycloheptènes : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Benzocycloheptènes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-11", "dateModified": "2025-03-08", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Benzocycloheptènes" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Hydrocarbures aromatiques polycycliques", "url": "https://questionsmedicales.fr/mesh/D011084", "about": { "@type": "MedicalCondition", "name": "Hydrocarbures aromatiques polycycliques", "code": { "@type": "MedicalCode", "code": "D011084", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Dibenzocycloheptènes", "alternateName": "Dibenzocycloheptenes", "url": "https://questionsmedicales.fr/mesh/D003986", "about": { "@type": "MedicalCondition", "name": "Dibenzocycloheptènes", "code": { "@type": "MedicalCode", "code": "D003986", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Amitriptyline", "alternateName": "Amitriptyline", "url": "https://questionsmedicales.fr/mesh/D000639", "about": { "@type": "MedicalCondition", "name": "Amitriptyline", "code": { "@type": "MedicalCode", "code": "D000639", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.100" } } }, { "@type": "MedicalWebPage", "name": "Butaclamol", "alternateName": "Butaclamol", "url": "https://questionsmedicales.fr/mesh/D002069", "about": { "@type": "MedicalCondition", "name": "Butaclamol", "code": { "@type": "MedicalCode", "code": "D002069", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.230" } } }, { "@type": "MedicalWebPage", "name": "Cyproheptadine", "alternateName": "Cyproheptadine", "url": "https://questionsmedicales.fr/mesh/D003533", "about": { "@type": "MedicalCondition", "name": "Cyproheptadine", "code": { "@type": "MedicalCode", "code": "D003533", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.340" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Loratadine", "alternateName": "Loratadine", "url": "https://questionsmedicales.fr/mesh/D017336", "about": { "@type": "MedicalCondition", "name": "Loratadine", "code": { "@type": "MedicalCode", "code": "D017336", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.340.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Loratadine", "alternateName": "Loratadine", "url": "https://questionsmedicales.fr/mesh/D017336", "about": { "@type": "MedicalCondition", "name": "Loratadine", "code": { "@type": "MedicalCode", "code": "D017336", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.340.500" } } }, { "@type": "MedicalWebPage", "name": "Maléate de dizocilpine", "alternateName": "Dizocilpine Maleate", "url": "https://questionsmedicales.fr/mesh/D016291", "about": { "@type": "MedicalCondition", "name": "Maléate de dizocilpine", "code": { "@type": "MedicalCode", "code": "D016291", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.380" } } }, { "@type": "MedicalWebPage", "name": "Nortriptyline", "alternateName": "Nortriptyline", "url": "https://questionsmedicales.fr/mesh/D009661", "about": { "@type": "MedicalCondition", "name": "Nortriptyline", "code": { "@type": "MedicalCode", "code": "D009661", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.535" } } }, { "@type": "MedicalWebPage", "name": "Protriptyline", "alternateName": "Protriptyline", "url": "https://questionsmedicales.fr/mesh/D011530", "about": { "@type": "MedicalCondition", "name": "Protriptyline", "code": { "@type": "MedicalCode", "code": "D011530", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.615.181.384.650" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Benzocycloheptènes", "alternateName": "Benzocycloheptenes", "code": { "@type": "MedicalCode", "code": "D001567", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Jiatian Li", "url": "https://questionsmedicales.fr/author/Jiatian%20Li", "affiliation": { "@type": "Organization", "name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China." } }, { "@type": "Person", "name": "Xiangwen Tan", "url": "https://questionsmedicales.fr/author/Xiangwen%20Tan", "affiliation": { "@type": "Organization", "name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China." } }, { "@type": "Person", "name": "Huanfeng Jiang", "url": "https://questionsmedicales.fr/author/Huanfeng%20Jiang", "affiliation": { "@type": "Organization", "name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China." } }, { "@type": "Person", "name": "Wanqing Wu", "url": "https://questionsmedicales.fr/author/Wanqing%20Wu", "affiliation": { "@type": "Organization", "name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Activin suppresses the expression of inflammatory genes and signaling proteins in human leukemia monocytic THP-1 cells.", "datePublished": "2023-11-15", "url": "https://questionsmedicales.fr/article/38015544", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.14715/cmb/2023.69.11.6" } }, { "@type": "ScholarlyArticle", "name": "Sequential Treatment with Activin and Hepatocyte Growth Factor Induces FOXM1 to Promote Colorectal Cancer Liver Metastasis.", "datePublished": "2022-12-23", "url": "https://questionsmedicales.fr/article/36591565", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1155/2022/8996203" } }, { "@type": "ScholarlyArticle", "name": "Paracrine activin B-NF-κB signaling shapes an inflammatory tumor microenvironment in gastric cancer via fibroblast reprogramming.", "datePublished": "2023-10-19", "url": "https://questionsmedicales.fr/article/37858201", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13046-023-02861-4" } }, { "@type": "ScholarlyArticle", "name": "Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case-control study.", "datePublished": "2023-05-23", "url": "https://questionsmedicales.fr/article/37221430", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12020-023-03402-x" } }, { "@type": "ScholarlyArticle", "name": "Transcriptomic Differences Underlying the Activin-A Induced Large Osteoclast Formation in Both Healthy Control and Fibrodysplasia Ossificans Progressiva Osteoclasts.", "datePublished": "2023-04-06", "url": "https://questionsmedicales.fr/article/37047804", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms24076822" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés polycycliques", "item": "https://questionsmedicales.fr/mesh/D011083" }, { "@type": "ListItem", "position": 3, "name": "Hydrocarbures aromatiques polycycliques", "item": "https://questionsmedicales.fr/mesh/D011084" }, { "@type": "ListItem", "position": 4, "name": "Benzocycloheptènes", "item": "https://questionsmedicales.fr/mesh/D001567" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Benzocycloheptènes - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Benzocycloheptènes", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-12", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Benzocycloheptènes", "description": "Comment identifier les benzocycloheptènes ?\nQuels tests sont utilisés pour les benzocycloheptènes ?\nLes benzocycloheptènes sont-ils détectables dans le sang ?\nY a-t-il des marqueurs spécifiques pour ces composés ?\nPeut-on utiliser l'imagerie pour les benzocycloheptènes ?", "url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Activins&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Benzocycloheptènes", "description": "Quels sont les effets secondaires des benzocycloheptènes ?\nLes benzocycloheptènes causent-ils des douleurs ?\nY a-t-il des symptômes neurologiques associés ?\nPeut-on observer des symptômes cutanés ?\nLes benzocycloheptènes affectent-ils le système respiratoire ?", "url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Activins&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Benzocycloheptènes", "description": "Comment prévenir l'exposition aux benzocycloheptènes ?\nY a-t-il des formations pour manipuler ces composés ?\nQuels sont les risques en milieu industriel ?\nDes réglementations existent-elles pour leur usage ?\nComment évaluer les risques d'exposition ?", "url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Activins&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Benzocycloheptènes", "description": "Comment traiter une intoxication aux benzocycloheptènes ?\nY a-t-il des antidotes pour ces composés ?\nQuels médicaments peuvent aider en cas d'allergie ?\nLes benzocycloheptènes nécessitent-ils une hospitalisation ?\nComment gérer les effets à long terme ?", "url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Activins&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Benzocycloheptènes", "description": "Quelles complications peuvent survenir avec ces composés ?\nLes benzocycloheptènes peuvent-ils causer des cancers ?\nY a-t-il des effets sur la reproduction ?\nPeut-on développer des allergies à long terme ?\nLes benzocycloheptènes affectent-ils le système immunitaire ?", "url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Activins&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Benzocycloheptènes", "description": "Qui est le plus à risque d'exposition ?\nL'âge influence-t-il la sensibilité ?\nY a-t-il des prédispositions génétiques ?\nLes antécédents médicaux jouent-ils un rôle ?\nL'environnement de travail influence-t-il le risque ?", "url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Activins&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier les benzocycloheptènes ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'identification se fait par des techniques de spectroscopie et de chromatographie." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour les benzocycloheptènes ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de toxicité et d'efficacité sont réalisés en laboratoire." } }, { "@type": "Question", "name": "Les benzocycloheptènes sont-ils détectables dans le sang ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent être détectés par des analyses spécifiques dans des échantillons biologiques." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs spécifiques pour ces composés ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs biologiques peuvent indiquer l'exposition à ces composés." } }, { "@type": "Question", "name": "Peut-on utiliser l'imagerie pour les benzocycloheptènes ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie moléculaire peut aider à visualiser leur distribution dans les tissus." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des benzocycloheptènes ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent provoquer des nausées, des vertiges ou des réactions allergiques." } }, { "@type": "Question", "name": "Les benzocycloheptènes causent-ils des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Des douleurs peuvent survenir en cas de toxicité ou d'allergie." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme des maux de tête ou des troubles de la coordination peuvent apparaître." } }, { "@type": "Question", "name": "Peut-on observer des symptômes cutanés ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées peuvent survenir en cas de réaction allergique." } }, { "@type": "Question", "name": "Les benzocycloheptènes affectent-ils le système respiratoire ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Une exposition excessive peut entraîner des irritations respiratoires." } }, { "@type": "Question", "name": "Comment prévenir l'exposition aux benzocycloheptènes ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des équipements de protection et suivre les protocoles de sécurité en laboratoire." } }, { "@type": "Question", "name": "Y a-t-il des formations pour manipuler ces composés ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des formations spécifiques sont souvent requises pour les chercheurs." } }, { "@type": "Question", "name": "Quels sont les risques en milieu industriel ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les travailleurs peuvent être exposés à des niveaux élevés sans protection adéquate." } }, { "@type": "Question", "name": "Des réglementations existent-elles pour leur usage ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des réglementations strictes encadrent leur utilisation en laboratoire et en industrie." } }, { "@type": "Question", "name": "Comment évaluer les risques d'exposition ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des évaluations de risque doivent être effectuées régulièrement dans les environnements de travail." } }, { "@type": "Question", "name": "Comment traiter une intoxication aux benzocycloheptènes ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut l'élimination de l'exposition et des soins symptomatiques." } }, { "@type": "Question", "name": "Y a-t-il des antidotes pour ces composés ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas d'antidote spécifique pour les benzocycloheptènes." } }, { "@type": "Question", "name": "Quels médicaments peuvent aider en cas d'allergie ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des antihistaminiques peuvent être utilisés pour traiter les réactions allergiques." } }, { "@type": "Question", "name": "Les benzocycloheptènes nécessitent-ils une hospitalisation ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Une hospitalisation peut être nécessaire en cas de symptômes graves." } }, { "@type": "Question", "name": "Comment gérer les effets à long terme ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi médical régulier est recommandé pour surveiller les effets à long terme." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec ces composés ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des lésions organiques peuvent survenir en cas d'exposition prolongée." } }, { "@type": "Question", "name": "Les benzocycloheptènes peuvent-ils causer des cancers ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un potentiel cancérigène, mais des recherches supplémentaires sont nécessaires." } }, { "@type": "Question", "name": "Y a-t-il des effets sur la reproduction ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des effets néfastes sur la reproduction ont été observés dans certaines études animales." } }, { "@type": "Question", "name": "Peut-on développer des allergies à long terme ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des sensibilisations peuvent se développer avec une exposition répétée." } }, { "@type": "Question", "name": "Les benzocycloheptènes affectent-ils le système immunitaire ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Une exposition prolongée peut altérer la fonction immunitaire, augmentant les infections." } }, { "@type": "Question", "name": "Qui est le plus à risque d'exposition ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les travailleurs en laboratoire et en industrie chimique sont les plus exposés." } }, { "@type": "Question", "name": "L'âge influence-t-il la sensibilité ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes et les personnes âgées peuvent être plus sensibles aux effets toxiques." } }, { "@type": "Question", "name": "Y a-t-il des prédispositions génétiques ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines prédispositions génétiques peuvent augmenter la sensibilité aux toxines." } }, { "@type": "Question", "name": "Les antécédents médicaux jouent-ils un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents d'allergies ou de maladies respiratoires augmentent le risque." } }, { "@type": "Question", "name": "L'environnement de travail influence-t-il le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un environnement de travail mal ventilé augmente le risque d'exposition." } } ] } ] }

Sources (139 au total)

Sequential Treatment with Activin and Hepatocyte Growth Factor Induces FOXM1 to Promote Colorectal Cancer Liver Metastasis.

Cancer stem cells (CSCs) are involved in liver metastasis in colorectal cancer (CRC). Activin and hepatocyte growth factor (HGF) are important regulators of stem cell properties. This study was perfor... HCT116 CRC cells were sequentially treated with activin and HGF and examined for migration and invasion in vitro and liver metastasis in vivo. RNA sequencing was performed to identify differentially e... Sequential treatment with activin and HGF-enhanced CRC cell migration, invasion, and metastasis. CXCR4 and AFP expressions were increased by activin and HGF treatment. Knockdown of FOXM1 blocked liver... Sequential treatment with activin and HGF accelerates CRC invasion and liver metastasis, which involves the upregulation and activation of FOXM1 and induction of CXCR4 and AFP....

Paracrine activin B-NF-κB signaling shapes an inflammatory tumor microenvironment in gastric cancer via fibroblast reprogramming.

Important roles of INHBB in various malignancies are increasingly identified. The underlying mechanisms in gastric cancer (GC) microenvironment are still greatly unexplored.... The clinical significance of INHBB and the correlation between INHBB and p-p65 in GC were assessed through analyzing publicly available databases and human paraffin embedded GC tissues. The biological... Our study showed that INHBB level was significantly higher in GC, and that increased INHBB was associated with poor survival. INHBB positively regulates the proliferation, migration, and invasion of G... GC cells p65/INHBB/activin B and fibroblasts p65/IL-1β signal loop led to the formation of a whole tumor-promoting inflammatory microenvironment, which might be a promising therapeutic target for GC....

Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case-control study.

The activins-follistatins-inhibins (AFI) hormonal system is considered to regulate muscle and bone mass. We aimed to evaluate AFI in postmenopausal women with an incident hip fracture.... In this post-hoc analysis of a hospital based case-control study, we evaluated circulating levels of the AFI system in postmenopausal women with a low-energy hip fracture admitted for fixation compare... Circulating levels of follistatin (p = 0.008), FSTL3 (p = 0.013), activin B and AB (both p < 0.001), as well as activin AB/follistatin and activin AB/FSTL3 ratios (p = 0.008 and p = 0.029, respectivel... Our data indicate no major changes in the AFI system in postmenopausal women at the time of hip fracture compared to postmenopausal women with osteoarthritis except for higher activin B and AB levels,... Clinical Trials identifier: NCT04206618....

Transcriptomic Differences Underlying the Activin-A Induced Large Osteoclast Formation in Both Healthy Control and Fibrodysplasia Ossificans Progressiva Osteoclasts.

Fibrodysplasia Ossificans Progressiva (FOP) is a very rare genetic disease characterized by progressive heterotopic ossification (HO) of soft tissues, leading to immobility and premature death. FOP is...

Activin type I receptor polymorphisms and body composition in older individuals with sarcopenia-Analyses from the LACE randomised controlled trial.

Ageing is associated with changes in body composition including an overall reduction in muscle mass and a proportionate increase in fat mass. Sarcopenia is characterised by losses in both muscle mass ... We compared regional body composition measured by DXA with genotypes for two polymorphisms (rs10783486, minor allele frequency (MAF) = 0.26 and rs2854464, MAF = 0.26) in the activin 1B receptor (ACVR1... Neither muscle mass nor strength showed any significant associations with either genotype in this cohort. Initial analysis of rs10783486 showed that males with the AA/AG genotype were taller than GG m... These data suggest that polymorphic variation in the ACVR1B locus could be associated with body composition in older males. The activin/myostatin pathway might offer a novel potential target to preven...

Activin A downregulates the CD69-MT2A axis via p38MAPK to induce erythroid differentiation that sensitizes BCR-ABL-positive cells to imatinib.

Induction of differentiation sensitizes chronic myeloid leukemia (CML) cells to the BCR-ABL inhibitor imatinib by mechanisms that remain unknown. We previously identified the BCR-ABL downstream effect...

Embryo Quality May Be Associated With Serum Inhibin B Levels but Not With Serum or Follicular Fluid Levels of Other Components of the Activin-Follistatin-Inhibin Axis.

We investigated the potential associations of embryo quality with serum and/or follicular fluid (FF) concentrations of the molecules of the activin-follistatin-inhibin (AFI) axis and antimüllerian hor... In this cross-sectional study, we measured AFI hormone and antimüllerian hormone levels in the serum and FF of follicles (n = 101) obtained from healthy oocyte donors who underwent an assisted reprodu... There was no difference between good and bad quality embryos in any of the molecules measured in FF. Moreover, there was no difference in the parameters measured in the serum among women according to ... Among the molecules of the AFI axis, only serum but not FF inhibin B levels were marginally associated with good quality embryo rates....

Activin B-activated Cdc42 signaling plays a key role in regulating adipose-derived mesenchymal stem cells-mediated skin wound healing.

In our previous study, activin B in combination with ADSCs enhances skin wound healing. However, the underlying molecular mechanisms are not well studied. Cdc42 is recognized to play a critical role i... Pull-down assay was performed to investigate the activity of Cdc42. The dominant-negative mutant of Cdc42 (Cdc42N17) was used to explore the role of Cdc42 in activin B-induced ADSCs migration, prolife... Cdc42N17 inhibited ADSCs migration, proliferation, and secretion induced by activin B. Furthermore, Cdc42N17-transfected ADSCs inhibited the wound closure rate and suppressed the expression of CD31 an... Our study indicates that Cdc42 plays a crucial role in ADSCs-mediated skin wound healing induced by activin B....